Complete Filing Data
Dermata Therapeutics, Inc. reported Stockholders Equity of $6.22 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Dermata Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income * | -$7.6M | -$12.3M | -$7.8M | -$9.6M | -$7.9M | -$3.2M |
| Research And Development Expense | $2.9M | $8.2M | $4.1M | $5.7M | $3.5M | $1.6M |
| Operating Income Loss | -$7.8M | -$12.5M | -$8.0M | -$9.7M | -$7.9M | -$3.2M |
| General And Administrative Expense | $4.3M | $4.0M | $4.0M | $4.4M | $1.6M | |
| Operating Expenses | $7.8M | $12.5M | $8.0M | $9.7M | ||
| Income Taxes Paid | $950.00 | $950.00 | $950.00 | $950.00 | $1.4K | $3.3K |
| Interest Expense | $45.6K | $197.3K | ||||
| Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities | $1.1M | $1.4M | $776.7K | |||
| Interest Income Expense Net | $63.6K | -$45.6K | ||||
| Net Income Loss Available To Common Stockholders Basic | -$9.6M | -$10.5M | -$3.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$1.7M | -$1.7M | -$2.3M | -$3.2M | -$2.8M | -$3.1M | -$1.7M | -$1.7M | -$2.2M | -$2.4M | -$2.7M | -$2.8M | -$1.7M | -$1.3M | -$2.3M | -$396.3K | -$597.4K | -$821.6K | -$1.4M |
| Research And Development Expense | $504.4K | $617.8K | $1.3M | $2.4M | $2.0M | $1.6M | $903.0K | $838.9K | $1.2M | $1.6M | $1.6M | $1.6M | $799.8K | $867.2K | $680.6K | $120.5K | $411.9K | ||
| Operating Income Loss | -$1.8M | -$1.8M | -$2.3M | -$3.2M | -$2.9M | -$3.2M | -$1.8M | -$1.7M | -$2.3M | -$2.4M | -$2.7M | -$2.8M | -$1.7M | -$1.3M | -$2.3M | -$540.1K | -$792.8K | ||
| General And Administrative Expense | $1.2M | $1.1M | $824.3K | $874.6K | $1.6M | $909.0K | $893.5K | $1.1M | $892.8K | $1.1M | $1.2M | $912.5K | $462.8K | $1.6M | $419.6K | $380.8K | |||
| Operating Expenses | $1.8M | $1.8M | $2.3M | $3.2M | $2.9M | $3.2M | $1.8M | $1.7M | $2.3M | $2.4M | $2.7M | $2.8M | |||||||
| Income Taxes Paid | $0.00 | $950.00 | |||||||||||||||||
| Interest Expense | $0.00 | $0.00 | $651.00 | $1.8K | $43.1K | $57.3K | $28.9K | ||||||||||||
| Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities | $369.5K | $429.8K | $590.5K | $178.3K | |||||||||||||||
| Interest Income Expense Net | $92.8K | $31.1K | $37.5K | $21.5K | $0.00 | $0.00 | $651.00 | ||||||||||||
| Net Income Loss Available To Common Stockholders Basic | -$4.3M | -$597.4K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity | $6.2M | $1.6M | $6.4M | $6.0M | $10.1M | -$3.2M | -$210.2K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $7.5M | $3.2M | $7.4M | $6.2M | $10.8M | $530.4K | |
| Retained Earnings Accumulated Deficit | -$73.2M | -$65.7M | -$53.4M | -$45.6M | -$36.0M | -$28.1M | |
| Prepaid Expense And Other Assets Current | $341.8K | $372.3K | $540.5K | $703.2K | $825.1K | $75.1K | |
| Liabilities And Stockholders Equity | $7.9M | $3.5M | $8.0M | $6.9M | $11.6M | $605.5K | |
| Liabilities | $1.6M | $2.0M | $1.6M | $922.6K | $1.5M | $3.8M | |
| Assets | $7.9M | $3.5M | $8.0M | $6.9M | $11.6M | $605.5K | |
| Accounts Payable Current | $460.8K | $808.0K | $866.0K | $496.7K | $515.2K | $104.3K | |
| Common Stock Value | $266.00 | $25.00 | $26.00 | $77.00 | $833.00 | $0.00 | |
| Cash And Cash Equivalents At Carrying Value | $7.5M | $3.2M | $10.8M | ||||
| Other Accrued Liabilities Current | $200.2K | $137.8K | $1.0M | $133.5K | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$4.3M | $1.2M | -$4.6M | $10.3M | |||
| Cash | $7.5M | $3.2M | $10.8M | ||||
| Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount | $1.0K | $187.00 | $287.00 | ||||
| Amortization Of Debt Discount Premium | $0.00 | $14.1K | $97.1K | ||||
| Conversion Of Common And Preferred Units And Warrants To Common And Preferred Stock And Warrants | $0.00 | $29.9M | $0.00 | ||||
| Accrued Liabilities And Other Liabilities | $1.2M | $1.2M | $757.6K | $425.9K | |||
| Convertible Subordinated Debt | $0.00 | $1.8M | |||||
| Issuance Of Common Stock And Warrants Net Of Issuance Costs Amount | $4.3M | ||||||
| Settlement Of Fractional Shares Paid In Cash Amount | -367.00 | -828.00 | -40.00 | ||||
| Redemption Of Series1C Preferred Stock | $0.00 | -$1.0M | $0.00 | ||||
| Preferred Stock Dividends Income Statement Impact | $2.3M | $0.00 | |||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $4.4M | -$4.3M | $10.3M | -$1.5M | |||
| Property Plant And Equipment Net | $0.00 | $0.00 | |||||
| Long Term Debt Current | $0.00 | $556.2K | |||||
| Liabilities Current | $1.5M | $3.8M | |||||
| Assets Current | $11.6M | $605.5K | |||||
| Depreciation Expense On Reclassified Assets | $0.00 | $322.00 | |||||
| Deemed Dividend Upon The Redemption Of Preferred Stock | $269.0K | $0.00 | |||||
| Convertible Long Term Notes Payable | $0.00 | $1.1M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $4.0M | $5.6M | $7.3M | $4.7M | $3.3M | $3.8M | $6.4M | $8.0M | $8.1M | $7.5M | $9.7M | $7.9M | $12.5M | -$505.8K | $712.0K | -$2.8M | -$2.2M | -$1.6M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $4.7M | $6.5M | $9.7M | $6.1M | $4.9M | $4.7M | $6.6M | $8.4M | $8.8M | $8.1M | $10.6M | $8.2M | $12.6M | |||||||
| Retained Earnings Accumulated Deficit | -$71.4M | -$69.7M | -$68.0M | -$62.5M | -$59.4M | -$56.5M | -$51.3M | -$49.5M | -$47.8M | -$43.9M | -$41.5M | -$38.8M | -$33.4M | -$31.7M | ||||||
| Prepaid Expense And Other Assets Current | $407.3K | $159.6K | $285.7K | $543.6K | $289.5K | $446.1K | $691.9K | $274.4K | $528.3K | $908.1K | $398.5K | $853.1K | $1.1M | $709.7K | ||||||
| Liabilities And Stockholders Equity | $5.1M | $6.6M | $10.0M | $6.7M | $5.2M | $5.2M | $7.3M | $8.7M | $9.3M | $9.0M | $11.0M | $9.0M | $13.7M | $1.1M | ||||||
| Liabilities | $1.1M | $1.0M | $2.7M | $1.9M | $1.9M | $1.4M | $916.8K | $682.9K | $1.2M | $1.5M | $1.4M | $1.2M | $1.2M | $1.6M | ||||||
| Assets | $5.1M | $6.6M | $10.0M | $6.7M | $5.2M | $5.2M | $7.3M | $8.7M | $9.3M | $9.0M | $11.0M | $9.0M | $13.7M | $1.1M | ||||||
| Accounts Payable Current | $453.4K | $413.7K | $1.4M | $863.6K | $1.3M | $822.5K | $474.5K | $437.8K | $492.9K | $483.7K | $608.8K | $662.2K | $769.9K | $881.3K | ||||||
| Common Stock Value | $84.00 | $64.00 | $603.00 | $168.00 | $69.00 | $666.00 | $319.00 | $319.00 | $239.00 | $1.2K | $1.0K | $833.00 | $833.00 | $191.00 | ||||||
| Cash And Cash Equivalents At Carrying Value | $4.7M | $6.5M | $9.7M | $6.6M | $8.4M | $8.8M | $6.2M | $8.1M | $10.6M | $8.2M | $12.6M | $427.2K | $530.4K | |||||||
| Other Accrued Liabilities Current | $57.3K | $442.4K | $245.1K | $714.2K | $425.9K | $1.0M | $757.7K | $529.3K | $425.4K | $586.5K | ||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$2.7M | $2.5M | -$2.6M | $800.0K | ||||||||||||||||
| Cash | $4.7M | $6.5M | $9.7M | $6.6M | $8.4M | $8.8M | $6.2M | $8.1M | $10.6M | $8.2M | $12.6M | $427.2K | $530.4K | |||||||
| Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount | $168.00 | $34.00 | $153.00 | $200.00 | $87.00 | |||||||||||||||
| Amortization Of Debt Discount Premium | $0.00 | $13.9K | ||||||||||||||||||
| Conversion Of Common And Preferred Units And Warrants To Common And Preferred Stock And Warrants | $0.00 | $29.9M | ||||||||||||||||||
| Accrued Liabilities And Other Liabilities | $657.9K | $612.6K | $1.3M | $1.1M | $591.2K | $549.2K | ||||||||||||||
| Convertible Subordinated Debt | $0.00 | $174.8K | ||||||||||||||||||
| Issuance Of Common Stock And Warrants Net Of Issuance Costs Amount | $1.5M | $4.2M | $4.3M | |||||||||||||||||
| Settlement Of Fractional Shares Paid In Cash Amount | -828.00 | -40.00 | ||||||||||||||||||
| Redemption Of Series1C Preferred Stock | ||||||||||||||||||||
| Preferred Stock Dividends Income Statement Impact | $2.3M | $0.00 | ||||||||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $6.6M | -$2.7M | ||||||||||||||||||
| Property Plant And Equipment Net | $0.00 | $0.00 | ||||||||||||||||||
| Long Term Debt Current | $0.00 | $0.00 | ||||||||||||||||||
| Liabilities Current | $1.2M | $1.6M | ||||||||||||||||||
| Assets Current | $13.7M | $1.1M | ||||||||||||||||||
| Depreciation Expense On Reclassified Assets | ||||||||||||||||||||
| Deemed Dividend Upon The Redemption Of Preferred Stock | $269.0K | $0.00 | ||||||||||||||||||
| Convertible Long Term Notes Payable | $0.00 | $0.00 |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$7.8M | -$11.2M | -$6.4M | -$8.8M | -$5.7M | -$4.0M |
| Share Based Compensation | $143.7K | $657.6K | $522.1K | $930.3K | $1.9M | |
| Increase Decrease In Accounts Payable | -$388.1K | -$108.5K | $369.3K | -$18.5K | $411.0K | -$232.9K |
| Net Cash Provided By Used In Financing Activities | $12.1M | $6.9M | $7.6M | $4.3M | $16.0M | $2.6M |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $407.2K | $331.7K | -$257.0K | $628.7K | -$21.6K | |
| Proceeds From Issuance Of Common Stock | $12.2M | $6.9M | $7.6M | $4.3M | $15.4M | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$30.5K | -$168.2K | -$162.7K | -$121.9K | ||
| Proceeds From Repayments Of Notes Payable | $0.00 | -$556.5K | -$810.2K | |||
| Increase Decrease In Prepaid Expense | -$121.9K | $750.1K | -$1.4K | |||
| Proceeds From Warrant Exercises | $977.00 | $1.1K | $187.00 | $287.00 | ||
| Proceeds From Convertible Debt | $1.6M | $3.0M | ||||
| Net Cash Provided By Used In Continuing Operations | $2.2M | -$792.0K | ||||
| Proceeds From Issuance Of Preferred Stock And Preference Stock | $0.00 | $18.8K | ||||
| Proceeds From Loan Originations1 | $0.00 | $133.6K | ||||
| Proceeds From Issuance Of Series1D Preferred Units | $570.0K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$1.9M | -$2.7M | -$1.6M | -$2.6M | -$776.2K | ||||
| Share Based Compensation | $37.8K | $39.2K | $37.2K | $21.0K | $19.6K | $587.2K | $131.3K | $212.9K | $1.2M |
| Increase Decrease In Accounts Payable | $102.1K | -$43.5K | -$3.8K | $147.0K | $383.8K | ||||
| Net Cash Provided By Used In Financing Activities | $8.5M | $0.00 | $4.2M | $0.00 | $1.6M | ||||
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -$208.4K | $288.2K | -$153.6K | $216.6K | |||||
| Proceeds From Issuance Of Common Stock | $8.5M | $0.00 | $4.2M | $0.00 | |||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$86.6K | -$94.4K | -$174.8K | ||||||
| Proceeds From Repayments Of Notes Payable | $0.00 | -$556.5K | |||||||
| Increase Decrease In Prepaid Expense | $27.9K | $245.7K | |||||||
| Proceeds From Warrant Exercises | $977.00 | $0.00 | $153.00 | ||||||
| Proceeds From Convertible Debt | $0.00 | $1.6M | |||||||
| Net Cash Provided By Used In Continuing Operations | $178.3K | $1.5M | |||||||
| Proceeds From Issuance Of Preferred Stock And Preference Stock | |||||||||
| Proceeds From Loan Originations1 | |||||||||
| Proceeds From Issuance Of Series1D Preferred Units | $0.00 | $570.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Diluted EPS * | -$8.16 | -$80.32 | -$39.99 | |||
| Common Stock Shares Authorized | 250.0M | 250.0M | 250.0M | 250.0M | 90.0M | |
| Common Stock Shares Outstanding | 2.7M | 251.7K | 262.0K | 770.1K | 8.3M | |
| Common Stock Shares Issued | 2.7M | 251.7K | 262.0K | 770.1K | 8.3M | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Weighted Average Basic And Diluted Common Units Shares | 2.9M | 690.7K | 4.3M | |||
| Net Loss Per Share Of Common Stock Basic And Diluted | ||||||
| Earnings Per Share Basic | $-8.16 | $-80.32 | $-0.87 | $-2.43 | $-1.69 | |
| Weighted Average Number Of Shares Outstanding Basic | 926.2K | 153.0K | 4.3M | 1.9M | ||
| Weighted Average Number Of Share Outstanding Basic And Diluted | ||||||
| Weighted Average Number Of Diluted Shares Outstanding | 926.2K | 153.0K | 194.9K | |||
| Earning Per Share Basic And Diluted | $-2.67 | $-13.92 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$1.65 | -$1.66 | -$0.45 | -$20.41 | -$41.82 | -$7.06 | -$0.86 | -$0.70 | -$0.31 | -$0.43 | |||||||
| Common Stock Shares Authorized | 250.0M | 250.0M | 250.0M | 250.0M | 250.0M | 250.0M | 250.0M | 250.0M | 250.0M | 250.0M | 90.0M | 90.0M | 4.4M | ||||
| Common Stock Shares Outstanding | 844.5K | 637.8K | 6.0M | 1.7M | 693.2K | 6.7M | 3.2M | 3.2M | 2.4M | 12.1M | 10.1M | 8.3M | 8.3M | 1.9M | |||
| Common Stock Shares Issued | 844.5K | 637.8K | 6.0M | 1.7M | 693.2K | 6.7M | 3.2M | 3.2M | 2.4M | 12.1M | 10.1M | 8.3M | 8.3M | 1.9M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Weighted Average Basic And Diluted Common Units Shares | 1.6M | 676.6K | 6.7M | 212.5K | 180.3K | 985.8K | 12.3M | 11.2M | 520.5K | 5.0M | 1.9M | 1.9M | |||||
| Net Loss Per Share Of Common Stock Basic And Diluted | $-0.54 | $-0.63 | $-2.27 | $-3.16 | $-3.90 | $-5.35 | $-0.86 | $-0.70 | $-1.21 | ||||||||
| Earnings Per Share Basic | $-1.65 | $-1.66 | $-0.45 | $-20.41 | $-41.82 | $-7.06 | |||||||||||
| Weighted Average Number Of Shares Outstanding Basic | 1.0M | 1.0M | 5.2M | 155.5K | 67.7K | 444.0K | |||||||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 5.0M | 1.9M | 1.9M | 1.9M | |||||||||||||
| Weighted Average Number Of Diluted Shares Outstanding | 1.0M | 1.0M | 5.2M | 155.5K | 67.7K | 444.0K | |||||||||||
| Earning Per Share Basic And Diluted | $-2.04 | $-4.18 | $-0.47 | $-8.09 | $-9.43 | $-2.27 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $143.7K | $657.6K | $522.1K | $1.1M | ||
| Additional Paid In Capital | $79.5M | $67.2M | $59.7M | $51.6M | $46.1M | $0.00 |
| Operating Costs And Expenses | $9.7M | $7.9M | $3.2M | |||
| Conversion Of Convertible Subordinated Promissory Notes To Series1D Preferred Units | $0.00 | $4.5M | $0.00 | |||
| Interest Paid | $1.4K | $56.7K | ||||
| Payment For Fractional Shares In Reverse Stock Split | -367.00 | -828.00 | 40.00 | 0.00 | ||
| Interest Income Other | $225.8K | $247.2K | $63.6K | |||
| Net Proceeds From Issuance Of Series1C Preferred Units | $0.00 | $250.0K | ||||
| Investment Income Interest | $215.0K | $225.8K | ||||
| Conversion Of Stock Amount Converted1 | $0.00 | $6.6K | $0.00 | |||
| Stock Granted During Period Value Sharebased Compensation | $1.6M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $37.8K | $39.2K | $37.2K | $21.0K | $19.6K | $587.2K | $131.2K | $131.2K | $131.3K | $179.4K | $205.9K | $531.6K | $142.7K | $114.0K | $1.2M | |
| Additional Paid In Capital | $75.3M | $75.3M | $75.3M | $67.3M | $62.7M | $60.3M | $57.7M | $57.6M | $55.9M | $51.4M | $51.2M | $46.6M | $45.9M | $31.2M | ||
| Operating Costs And Expenses | $2.4M | $2.7M | $2.8M | $1.7M | $1.3M | $2.3M | $540.1K | |||||||||
| Conversion Of Convertible Subordinated Promissory Notes To Series1D Preferred Units | $0.00 | $4.5M | ||||||||||||||
| Interest Paid | $0.00 | $473.00 | ||||||||||||||
| Payment For Fractional Shares In Reverse Stock Split | 0.00 | 40.00 | ||||||||||||||
| Interest Income Other | $52.5K | $54.6K | $69.3K | $92.8K | $31.1K | $37.5K | ||||||||||
| Net Proceeds From Issuance Of Series1C Preferred Units | ||||||||||||||||
| Investment Income Interest | $68.7K | $71.6K | $36.2K | $52.5K | $54.6K | $69.3K | ||||||||||
| Conversion Of Stock Amount Converted1 | ||||||||||||||||
| Stock Granted During Period Value Sharebased Compensation | $531.6K | $142.7K | $114.0K | $1.2M |
Most recent annual filing with the SEC: March 26, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.